A group of scientists from Stanford University in collaboration with Genentech, a biotechnology corporation, has created a system based on AI that can be used to safely add participants to clinical trials that they may have previously been barred from. The group’s findings were reported in the “Nature” journal, with Columbia University’s James Rogers and Chunhua Weng publishing a “News & Views” piece on the group’s research in the same journal.
Many countries have put in place measures to ensure that all drugs undergo clinical trials before being approved for use by patients in order to demonstrate that, in addition to being safe for use, the drugs offer the intended therapy.
However, clinical trials in many countries, including the United States, are affected by one serious obstacle: the individuals who have the drugs administered to them in clinical trials have to be vetted using a specific selection criterion. The researchers note that a majority of clinical trials do not, for instance, permit pregnant women to participate in them. In addition, most of the trials have age requirements.
Moreover, the trials do not permit individuals who suffer from conditions that aren’t being tested to take part in the studies. This criterion unnecessarily bars many people who may benefit from the therapy and also decreases the available pool of potential volunteers.
This explains why the researchers, through their efforts, have attempted to overcome this issue by developing an artificial intelligence-based system that can be used to safely include more individuals in clinical trials.
The AI system, dubbed the Trial Pathfinder, is a computer system that can be used to compare the survival outcomes of participants of clinical trials through its huge database. The system learns more about patients who are less or more likely to experience issues in a clinical trial for an experimental drug as it examines the data. It bases predicted outcomes on various factors, which include an individual’s medical history, whether they are pregnant, their weight and also their age.
The system then mimics a clinical trial that includes the individuals who had previously been left out. The information the system provides for its mock clinical trial is then utilized by researchers when establishing the criterion for selection for their actual clinical trial.
The researchers tested the system using actual data on specific applications such as various types of cancer. They noted that the system demonstrated that it was capable of growing the allowable populations of participants in such clinical trials by roughly 53%.
This AI system could introduce a new dimension to the work done by different biomed companies, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), as they seek for better remedies to the health challenges humans face.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.